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ABSTRACT 
Tetracyclines, especially doxycycline, play a role in the regulation of inflammation, immunomodulation, cell proliferation, 
and angiogenesis. Treatment of corneal angiogenesis or choroidal neovascularization with tetracyclines has been shown 
to be effective in animal models. The aim of this study was to evaluate the efficacy of oral doxycycline in reducing the 
total number of intraocular injections needed for controlling neovascular age-related macular degeneration in human 
patients. In this interventional case series, 28 random consecutive patients with neovascular age-related macular 
degeneration from Farabi  Eye Hospital, Tehran, Iran were treated for 4 months with 200 mg doxycycline once a day 
after the first intravitreal bevacizumab injection in addition to standard therapy in agreement with as-needed regimen. 
After 12 months of follow-up, total number of injections, foveal thickness and visual acuity were compared to those at 
baseline and of similar studies. Similar to standard treatment, co-treatment with doxycycline was able to control active 
disease (intraretinal or subretinal fluid or leakage, new-onset of macular hemorrhage, and reduction of visual acuity 
more than 5 letters based on Early Treatment Diabetic Retinopathy Study [ETDRS] charts) yet with fewer injections (for 
current study and standard treatment, respectively 3.14 vs. 5.92, P < 0.001). Furthermore, while better control of the 
foveal thickness was achieved (P < 0.001), vision improvement was similar to that achieved with standard therapy (P > 
0.05). If confirmed in larger studies, the findings of this interventional case series could provide a strategy to control 
neovascular age-related macular degeneration with fewer intraocular bevacizumab injections by co-administering a well-
known oral agent—doxycycline. 
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INTRODUCTION
In developed countries, age-related macular 
degeneration (AMD) is the foremost reason of legal 
blindness among individuals over 50 years old. In AMD, 
central vision impairment is engendered due to a 
degenerative process of the macula. Since AMD is a 
multifactorial spectrum of macular degeneration, at the 
point of imbalance between inhibiting and promoting 
neovascularization factors, neovascular AMD (nAMD) 
may occur. Inhibition of vascular endothelial growth 
factor (VEGF) by numerous intravitreal injections has 
been the basis of nAMD treatment over the past 10 years 
[1]. Anti-VEGF compounds, such as pegaptanib, 
bevacizumab, ranibizumab, and aflibercept, are 
commonly used to treat nAMD. However, in spite of 
treatment strategies such as treat-and-extend or as-
needed (pro re nata [PRN]) regimens, management of 
choroidal neovascularization (CNV) is still a dilemma [2]. 
Alongside the results of clinical studies, outcomes of 
everyday practice show that a treatment regimen with 
frequent injections may be less favorable and even pose 
an enormous burden on health care systems [3]. To 
reduce the need for multiple intraocular injections, some 
authors have suggested co-treatments should be 
considered for patients [1, 4]. 
In addition to their well-known bacteriostatic properties, 
tetracyclines, especially doxycycline and minocycline, 
regulate inflammation, immunomodulation, cell 
proliferation, and angiogenesis. In particular, the anti-
angiogenic properties of doxycycline—which have been 
recognized since the 1990s—have been shown to play a 
role in the treatment of pathologic angiogenesis [5]. Such 
properties have encouraged us to conduct an 
interventional case series as a pilot stage for a 
randomized control trial (RCT) to improve management 
of CNV by administration of doxycycline. To our 
knowledge, this is the first case series of its type in 
human subjects. The findings of this case series could 
provide a strategy to reduce the total number of 
intraocular bevacizumab injections and related problems 
by co-administering a well-known oral agent—
doxycycline. 
MATERIALS AND METHODS 
A total of 28 random consecutive patients from Farabi 
Eye Hospital, Tehran, Iran met the inclusion criteria 
(Table 1) and were enrolled in this interventional case 
series. The study was conducted between October 2014 
and March 2015. Each patient signed an informed 
consent form that was provided by our ethics committee 
in agreement with the Declaration of Helsinki. 
According to our conventional treatment protocol for 
active lesions of nAMD, patients were treated with 
1.25mg bevacizumab (Avastin®, Genentech, South San 
Francisco, CA, USA) by a single intravitreal injection in a 
volume of 0.05 cc under topical anesthesia in the 
operation room. To check for any sign of disease 
activation or indication for re-treatment, patients were 
evaluated monthly for 6 months and thereafter every 3 
months for the subsequent 6 months. In each session, 
the following examinations were performed: fundus 
examination, best-corrected visual acuity (BCVA), 
anterior chamber examination, and optical coherence 
tomography (OCT; Spectralis®, Heidelberg Engineering, 
Heidelberg, Germany). Fluorescein angiography (FA; HRA 
2, Heidelberg Engineering) was requested in the first visit 
and in special cases during follow-up. In case of suspicion 
of retinal angiomatous proliferation or polypoidal 
choroidal vasculopathy, indocyanine green (ICG) imaging 
was performed. Re-treatment indications are listed in 
Table 1. The re-treatment dose of intravitreal 
bevacizumab was equal to the initial dose. In the case of 
scar formation or lack of re-treatment indication, lesions 
were considered as inactive and patients were followed 
up according to the schedule. 
In this study, in addition to our conventional approach, 
the patients were co-treated with oral doxycycline 
(DoxyHEXAL® 200 mg; Hexal, Holzkirchen, Germany) 
once a day for 4 months after the first injection of 
bevacizumab. They were trained to take doxycycline 
correctly and were informed about the symptoms of 
disease activation; besides, they were screened for the 
incidence of pseudotumor cerebri, hepatotoxicity, 
azotemia, photosensitivity, rash, oral or vaginal 
candidiasis, and gastrointestinal adverse effects. The 
following data were collected: age, sex, history of 
cardiovascular diseases, hypertension, smoking history, 
type and size of lesion, initial and final visual acuity score 
based on Early Treatment Diabetic Retinopathy Study 
(ETDRS) charts, central thickness of the fovea according 
to the OCT reports, need for re-treatment, number of 
consumed doxycycline tablets, and total number of 
injections needed to control the disease in the first year. 
Active lesions of nAMD were categorized into occult, 
predominantly classic, and minimally classic. All patients 
with active nAMD were entered into the study regardless 
of their lesion subtype or baseline lesion size and visual 
acuity; however, in patients with bilateral involvement, 
only the left eye was included. On the condition that a 
patient’s best corrected visual acuity (BCVA) was below 
the lower threshold of standard ETDRS charts, the visual 
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acuity score was calculated using the logarithm of the 
minimum angle of resolution (logMAR) equivalent value, 
which was obtained by conversion of counting fingers 
results to the logarithmic scale. In this study, severe 
visual loss or significant visual gain was considered when 
the visual acuity score changed by > 15 points. 
 
Table 1: Inclusion/Exclusion Criteria and Re-treatment Indications 
Inclusion criteria 
Subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) 
Lesion size ≤2.5 disc diameter) 
Treatment-naïve patients 
No history of systemic disease or myocardial infarction 
Age >50 years old 
Exclusion criteria 
Any history of hypersensitivity to tetracyclines or a family history of breast cancer 
Pregnant or lactating women 
Previous treatment for neovascular AMD, subfoveal or juxtafoveal laser treatment, or a positive history of ocular surgery 
CNV due to causes other than AMD 
Patients with any retinal vasculopathies, including diabetic retinopathy, retinal vein occlusions, vitreomacular adhesion, 
fibrovascular scar, or geographic atrophy in the study eye 
Acute ocular or periocular infection 
Glaucoma or intraocular pressure in the study eye >22 mmHg 
Re-treatment indications 
Active CNV on examination or imaging 
Intraretinal or subretinal fluid or leakage 
New-onset macular hemorrhage 
Visual acuity depletion more than 5 letters 
 
The Shapiro–Wilk test was employed to evaluate normal 
distribution of quantitative variables. One-sample t-test, 
independent samples t-test, and paired-samples t-test 
were run to assess the significance of the differences 
between mean values. SPSS version 19.0 (SPSS Inc., 
Chicago, IL, USA) was used to carry out all statistical 
analyses. The significance level was set at P < 0.05. Data 
are presented here as means ± standard deviation (SD). 
RESULTS 
Six patients out of the initial 28 study subjects were 
excluded from the study because of either lack of 
adhesion to the therapeutic plan or loss to follow-up. The 
mean age of our remaining subjects was 75.5 ± 7.7 years. 
Of the 22 remaining patients, 12 (54.5%) were female. 
Hypertension and a positive history of smoking were 
found in 13 (59.1%) and 8 (36.4%) patients, respectively. 
Eye involvement (laterality) was as follows: right in 9 
cases (40.9%), left in 4 (18.2%), and bilateral in 9 (40.9%). 
The type of lesion was as follows: occult in 6 cases 
(27.3%), predominantly classic in 13 (59.1%), and 
minimally classic in 3 (13.6%). On the basis of the optic 
disc diameter (DD), the average initial lesion size was 
1.25 ± 0.65 DD. Mean initial and final visual acuity scores 
based on ETDRS charts were 28.5 ± 22.57 and 36.45 ± 
26.66, respectively. According to the OCT reports, mean 
initial and final central foveal thickness were 445.14 ± 
63.69 m and 212.45 ± 29.50 m, respectively. Five 
patients (22.7%) had a significant increase in visual acuity 
(i.e., an increase of >15 points in the visual acuity score) 
and 6 (27.3%) had mild to moderate visual gain. Two 
patients (9%) experienced mild to moderate visual loss 
and 1 (4.5%) experienced a decrease in visual acuity 
depletion of >15 points. Visual acuity did not change in 8 
patients (36.5%). Among the patients who completed the 
study, five complained about gastrointestinal side effects 
such as heartburn and dyspepsia. There was no evidence 
for pseudotumor cerebri, hepatotoxicity, azotemia, 
photosensitivity, rash, or oral or vaginal candidiasis. The 
data of six patients who were lost to follow-up were 
excluded from the statistical analysis. All quantitative 
variables followed a normal distribution (P > 0.05 by 
Shapiro–Wilk test). Sex, history of hypertension, and 
smoking did not affect the size or thickness of the lesion, 
visual acuity score, or the number of injections required 
for disease control (P > 0.05 for all comparisons). Co-
treatment of active nAMD with intraocular bevacizumab 
and oral doxycycline improved the final visual acuity 
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score and reduced the final central foveal thickness 
compared to initial records (mean visual acuity score: 
36.45 ± 26.6 points vs. 28.5 ± 22.5 points, respectively, P 
= 0.03; mean foveal thickness: 212.45 ± 29.5 m vs. 
445.14 ± 63.7 m, respectively, P < 0.001 by paired-
sample t-test). After 12 months of follow-up, the average 
total number of injections needed to control disease 
activity was 3.18 ± 0.79 injections/year (Table 2).  
 
Table 1: Patient Baseline Characteristics and Response to Co-Treatment of nAMD by Intraocular Bevacizumab and Oral Doxycycline. Data are Means ± 
Standard Deviation unless Otherwise Stated 
 Values 
Age, years 75.5 ± 7.7 
Sex, female:male ratio, n (%) 12 (54.5%):10 (45.5%) 
Initial lesion size, disc diameter 1.25 ± 0.65 
Initial visual acuity score * 28.5 ± 22.57 
Initial thickness of the foveal central portion, m  445.14 ± 63.69 
Visual acuity score change 7.92 ± 16.89 (P = 0.03) 
Foveal thickness change, m 232.68 ± 69.25 (P < 0.001) 
Final visual acuity score 36.45 ± 26.66 
Final central foveal thickness, micrometer 212.45 ± 29.50 
Number of consumed doxycycline tablets 212.5 ± 7.5 
Total number of injections in 12 months 3.18 ± 0.79 
* based on Early Treatment Diabetic Retinopathy Study (ETDRS) charts 
 
DISCUSSION
Nowadays, various anti-VEGF agents, such as pegaptanib, 
bevacizumab, ranibizumab, and aflibercept, are available 
to control nAMD lesions. The better outcomes of 
bevacizumab compared to ranibizumab and its 
affordable price compared to ranibizumab and 
aflibercept, make off-label application of bevacizumab 
the first choice in many clinical centers, including ours 
[6]. Due to the burden of AMD treatment on health care 
systems and patients, the overall tendency is to reduce 
the total number of intraocular injections or improve the 
results of standard management in more patients [1]; 
besides, concerns about frequent intraocular injections 
may limit the administration of anti-VEGF agents in 
patients with AMD. Although there are some doubts 
about the outcomes of anti-VEGF administration by 
treat-and-extend or as-needed regimens [6, 7], these 
protocols—which are based on periodic examinations, 
disease status, and a patient's need for re-treatment—
have more acceptance than either fixed doses or 
monthly administration of anti-VEGF agents [8, 9]. Rather 
than generating new anti-VEGF agents, such as 
brolucizumab, designed ankyrin repeat proteins 
(DARPins), and topical tyrosine kinase inhibitors [10], 
many trials have been using anti-VEGF agents in 
combination with other treatments such as 
photodynamic therapy (PDT) [11], stereotactic radiation 
therapy (SRT) [12], epimacular brachytherapy, and other 
mediators of angiogenesis and inflammation [10, 13-15]. 
However, the results are controversial. According to 
impact of tetracyclines -especially doxycycline- on 
inflammation, immunomodulation, cell proliferation and 
angiogenesis, we decided to study the efficacy of 
doxycycline in reducing the total number of intraocular 
injections in a year. nAMD is characterized by CNV and 
the formation of abnormal vessels, which may leak and 
lead to subretinal collections. VEGF is involved in both 
CNV and vascular hyperpermeability from new and old 
vessel beds and is currently the main target for 
pharmacological treatment of active nAMD. Matrix 
metalloproteinases (MMPs) also contribute to the 
progression of AMD. MMPs, especially MMP-2 and 
MMP-9, decrease the levels of pigment epithelium-
derived factor (PEDF), the main antagonist of VEGF in the 
retinal pigment epithelium (RPE). Furthermore, VEGF 
induces MMP-9 activity by increasing nitric oxide levels. 
Initially, the effects of doxycycline on MMPs were 
considered because of its effects on angiogenesis, but 
further studies revealed more mechanisms beyond the 
inhibition of MMPs [5, 16-18]. In addition to undesirable 
angiogenesis in nAMD, endothelial cell junctions in new 
vessels are more permeable than mature ones, and VEGF 
aggravates this impairment. Doxycycline could prevent 
the effects of VEGF while inducing vascular endothelial 
(VE)-cadherin expression on endothelial cells [19]. In 
2006, Dehrah et al. stated that doxycycline could 
decrease the serum level of VEGF in lymphatic filariasis 
[20]. Pimenta et al. showed that 12-month 
administration of doxycycline is safe and effective for the 
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treatment of lymphangioleiomyomatosis and for 
lowering urine and plasma levels of MMPs; however, the 
authors concluded that the therapeutic outcomes could 
be not explained solely by MMP blockade [21, 22]. There 
is increasing evidence for the protective effect of topical 
or oral doxycycline against corneal neovascularization 
[23, 24]. In 2009, Samtani et al. successfully inhibited the 
progression of CNV in rats by orally administration of 
doxycycline [17]. Likewise, Cox et al. had similar results in 
a murine model of CNV and pterygium growth [25]. It has 
been demonstrated that co-treatment of corneal 
angiogenesis with doxycycline and bevacizumab is more 
effective than monotherapy [26]. However, in one pilot 
study by Sivaprasad et al., the outcomes of foursome 
combination therapy for nAMD with PDT, intravitreal 
ranibizumab, dexamethasone, and oral minocycline were 
considered equivalent to those of combination treatment 
with standard PDT and ranibizumab [27]. In 2012, Robert 
et al. reported the successful treatment of CNV due to 
Bartonella henselae in a young patient with doxycycline 
and intravitreal bevacizumab [28]. In our study, no 
significant side effects, such as bleeding, cardiovascular 
events, stroke, and sudden death, were observed. The 
only reported side effect was heartburn in 5 patients 
(22.7%), which resolved after following the instructions. 
Symptom severity did not interfere with the continuation 
of the study. 
As mentioned above, it has been inferred that co-
treatment of nAMD with intraocular bevacizumab 
(number of injections in the first year, 3.18 ± 0.79) and 
oral doxycycline was effective in visual acuity 
improvement and reduction of foveal thickness (visual 
acuity: 7.92 ± 16.89 points, P = 0.03; foveal thickness: 
232.68 ± 69.25 m, P < 0.001). Although there were 
some differences between the baseline characteristics of 
our patients and those of comparable studies with a PRN 
anti-VEGF protocol, the present visual acuity changes are 
in agreement with previously reported outcomes (P > 
0.05 in both studies) [27, 29]. Compared to the previous 
studies, in our patients, foveal thickness regression was 
greater (foveal thickness change: 66.3 m and 85.3 m 
versus 232.68 m, respectively, P < 0.001), but this 
difference could be interpreted as a consequence of the 
worse initial situation in our subjects. Since our study 
included all patients, we concluded that the combination 
therapy with oral doxycycline could be useful for patients 
with advanced disease as well as cases with early lesions. 
While in our case series, the total number of injections 
was 3.18 ± 0.79 injections/year in average (P < 0.001), in 
studies with similar re-treatment indications with a PRN 
protocol for intravitreal bevacizumab monotherapy, the 
mean total number of injections was 7.7 and 5.92 in the 
first year, respectively [6, 29]. Our results are in 
agreement with another pilot study that evaluated the 
effect of combination therapy with PDT, intravitreal 
ranibizumab, dexamethasone, and oral minocycline (P = 
0.212) [27]. Although the authors concluded their results 
were similar to those of clinical trials on combination 
therapy with PDT and anti-VEGF, oral administration of 
tetracyclines, especially doxycycline, is as effective as co-
treatment of CNV with standard PDT. There are 
numerous limitations in this study, namely the small 
sample size, lack of a control group, inability to evaluate 
doxycycline plasma levels, and single-center design. The 
low number of subjects did not allow us to interpret the 
results according to the baseline characteristics of the 
patients. The short follow-up time and loss to follow-up 
prevented us to uncover whole adverse effects. 
Unfortunately, we were unable to identify the cause of 
loss to follow-up or inappropriate adhesion to the 
therapeutic plan by the six excluded patients. In 
conclusion, even in patients with advanced nAMD, oral 
administration of doxycycline could reduce the need of 
intravitreal anti-VEGF re-injection. Larger, controlled 
clinical trials are needed to confirm the role of 
tetracyclines in the co-treatment of nAMD. 
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